ClinicalTrials.gg
Enrolling by invitationNCT07381998Updated Feb 2, 2026

Effects of Total Thyroid Removal on Parathyroid Function and Quality of Life

An interventional study of high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2) and Ommit routine blood test post operative day 1 in Hypoparathyroidism Post-surgical and Quality of Life, sponsored by Aarhus University Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Hypoparathyroidism with a site in Denmark — 3 open to participants now, 6 under way, 2 of them phase 3. Hypoparathyroidism · Denmark.

Planned enrollment
4th of 15
150 · median 78
Started
2026
the only one that year
No phase
5 of 21
2 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
Aarhus University Hospital

Among the 21 studies in Hypoparathyroidism with a site in Denmark, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 5 with no phase, and was the 21st registered.

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

Browse Hypoparathyroidism studies →

Open to participants now

3 of the 21 studies in Hypoparathyroidism with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hypoparathyroidism with a site in Denmark, or all of them as a file.
02

Study summary

Postoperative hypoparathyroidism (hypoPT) is the most frequent complication after total thyroidectomy (TT). It is caused by impaired parathyroid function, leading to low calcium levels, patient discomfort, reduced quality of life (QoL), and increased healthcare costs. Traditionally, all TT patients undergo routine postoperative blood testing and standard calcium supplementation, despite varying individual risk.

This investigator-initiated project aims to improve patient outcomes by using intraoperative parathyroid hormone (ioPTH) measurements to guide postoperative care. The ioPTH decline reflect parathyroid function immediately after surgery and can identify patients at high or low risk of hypoPT.

The study is designed as a prospective, randomized controlled trial (RCT) with two arms:

Arm A (\<75% ioPTH decrease): Patients randomized to either omission of routine postoperative calcium/PTH blood tests or standard monitoring.

Arm B (>75% ioPTH decrease): Patients randomized to either early high-dose calcium and vitamin D supplementation or standard therapy.

Primary outcomes are calcium and PTH levels postoperatively, incidence of hypocalcemia, and healthcare resource use. Secondary outcomes include QoL assessed by validated questionnaires (ThyPro39, SF-36, HPQ27), transient and permanent hypoPT rates, and other surgical complications.

By tailoring care to individual risk, the study aims to safely reduce unnecessary blood tests and optimize early treatment for high-risk patients. This approach has the potential to shorten hospital stays, reduce symptoms, improve QoL, and lower costs. The findings may influence clinical guidelines nationally and internationally, supporting more personalized and evidence-based management of TT patients.

03

Conditions studied

  • Hypoparathyroidism Post-surgical
  • Quality of Life

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years) undergoing Total thyroidectomy with intraoperative PTH measurements.

Exclusion criteria

Exclusion Criteria:

  • Malabsorption (intestinal resection or gastric by-pass).
  • Renal insufficiency (\<30 ml/min) or deemed clinically high-risk requiring mandatory biochemical monitoring.
  • Hypercalcemia (Ca2+ > 1.32 mmol/L).
  • Previous thyroid or parathyroid operations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    <75 % fall in intraoperative parathyroidhormone

    Standard blood test on post operative day 1 including PTH and P-ca

  • Experimental
    <75 % fall in intraoperative parathyroidhormone experimental

    Ommit routine blood test on post operative day 1

    Diagnostic Test: Ommit routine blood test post operative day 1

  • No intervention
    >75% fall in intraoperative parathyroidhormone

    Standard treatment

  • Experimental
    >75% fall in intraoperative parathyroidhormone experimental

    Start in Unikalk 4 times per day + d-vitamin + alfacalcidol 2 microgram 2 times per day.

    Drug: high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2)

Interventions

  • Drughigh-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2)

    Standard postoperative treatment includes low-dose calcium (400 mg x 2) and vitamin D (19 mikg x 2) is initiated for all patients. In the intervention group, patients are randomized to standard low-dose (control group) or standard high-dose treatment including immediate postoperative initiation of high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2). In the control group, treatment with active vitamin D is only initiated in case of low PTH (\<1.0 pmol/L) and low Ca2+ (\<1.10 mmol/L).

  • Diagnostic testOmmit routine blood test post operative day 1

    Patients are randomized to either clinical monitoring only, without routine postoperative POD1 measurements of Ca2+ and PTH in one group or standard postoperative care, including routine blood tests for Ca2+ and PTH at POD1. All patients will have Ca2+ and PTH measured after the first postoperative week

06

What researchers measure

Primary outcomes

  1. Plasma ionized calcium (Ca2+) concentration at postoperative week 1 (POD7), by POD1 biochemical testing status

    Comparison of plasma ionized calcium (Ca2+ mmol/L) and parathyroid hormone (PTH pmol/L) after one postoperative week between patients with and without biochemical measurements at post operative day 1 (POD1.)

    Time frame: 2 years

  2. Plasma ionized calcium (Ca2+ mmol/L) concentration on postoperative day 2 (POD2)

    Comparison of plasma ionized calcium (Ca2+ mmol/L) between groups at postoperative day 2 (POD2).

    Time frame: 1 year

Secondary outcomes

  1. Incidence of clinically significant hypocalcemia requiring medical intervention through 12 months

    Proportion of participants with clinically significant hypocalcemia, defined as plasma ionized calcium (Ca2+) \< 1.10 mmol/L and/or presence of symptoms of hypocalcemia, necessitating medical intervention (e.g., IV calcium and/or initiation or escalation of oral calcium ± vitamin D). Incidence will be compared between arms.

    Time frame: 2 years

  2. Number of postoperative blood tests through 12 months

    Total number of postoperative blood tests per participant (count), compared between arms.

    Time frame: 2 years

  3. Length of index hospital stay after surgery

    Duration of initial postoperative hospital stay per participant, measured in days (or hours), compared between arms.

    Time frame: 2 years

  4. Change from baseline in Thyroid-Specific Patient-Reported Outcome measure (ThyPRO-39) score through 12 months

    Change from baseline in Thyroid-Specific Patient-Reported Outcome measure (ThyPRO-39) score assessed at baseline and at 1 week, 2 months, 6 months, and 12 months. Scores are transformed to a 0-100 scale (minimum 0, maximum 100); higher scores indicate worse thyroid-related quality of life (more symptoms/impairment).

    Time frame: 2 years

  5. Change from baseline in 36-Item Short Form Health Survey (SF-36) score through 12 months

    Change from baseline in 36-Item Short Form Health Survey (SF-36) domain scores assessed at baseline and at 1 week, 2 months, 6 months, and 12 months. Each domain score ranges from 0 to 100 (minimum 0, maximum 100); higher scores indicate better health status/quality of life.

    Time frame: 2 years

  6. Change from baseline in Hypoparathyroidism Patient Questionnaire (HPQ-27/HPQ-28) score through 12 months

    Change from baseline in Hypoparathyroidism Patient Questionnaire (HPQ-27/HPQ-28) score assessed at baseline and at 1 week, 2 months, 6 months, and 12 months. Scores are transformed to a 0-100 scale (minimum 0, maximum 100); higher scores indicate worse disease control / greater symptom burden

    Time frame: 2 years

  7. Adverse events frequency through 12 months

    Number and proportion of participants experiencing any adverse event, compared between arms.

    Time frame: 2 years

  8. Incidence of transient hypoparathyroidism through 12 months

    Proportion of participants with transient hypoparathyroidism, defined as plasma ionized calcium (Ca2+) \< 1.10 mmol/L and/or need for treatment with alfacalcidol, with subsequent resolution (i.e., no longer meeting the definition and not requiring alfacalcidol) within 12 months. Incidence will be compared between arms.

    Time frame: 2 years

  9. Incidence of permanent hypoparathyroidism at 12 months

    Proportion of participants meeting the hypoparathyroidism definition (plasma ionized calcium (Ca2+) \< 1.10 mmol/L and/or need for alfacalcidol) that persists at 12 months, with continued need for alfacalcidol beyond 12 months. Incidence will be compared between arms.

    Time frame: 2 years

  10. Incidence of postoperative bleeding complication through 30 days

    Proportion of participants with postoperative bleeding/hematoma requiring intervention (e.g., re-operation), compared between arms.

    Time frame: 2 years

  11. Incidence of postoperative infection through 30 days

    Proportion of participants with postoperative infection requiring antibiotics and/or drainage, compared between arms.

    Time frame: 2 years

  12. Incidence of nerve injury through 12 months

    Proportion of participants with postoperative nerve injury, defined as recurrent laryngeal nerve palsy, assessed based on patient-reported voice function and confirmed by laryngoscopy, compared between arms.

    Time frame: 2 years

  13. Number of resected parathyroid glands

    Number of resected parathyroid glands per participant (count) based on pathology report, compared between arms.

    Time frame: 2 years

  14. Number of lymph nodes removed

    Number of lymph nodes removed per participant (count) based on pathology report, compared between arms.

    Time frame: 2 years

  15. Thyroid pathology findings

    Final thyroid pathology diagnosis based on the postoperative histopathology report, categorized as cancer, goiter, or thyrotoxicosis-related pathology, and compared between arms

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Feb 2, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2028
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07381998
Responsible party
Khalil Rafiqi (Medical Doctor, PhD student, Aarhus University Hospital) — Principal investigator
First posted
Feb 2, 2026
Start date
Jan 1, 2026
Primary completion
Jul 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 2, 2026

Study contacts

Lars Rolighed, Professor, PhD, FEBS
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion